Gi-6301 (Not yet branded)
Other Medications
Description
GI-6301 is a therapeutic cancer vaccine that targets the brachyury protein, a transcription factor overexpressed in various solid tumors including colorectal cancer. This immunotherapy approach aims to stimulate the patient's immune system to recognize and attack cancer cells expressing brachyury. The vaccine is designed to elicit both humoral and cellular immune responses against brachyury-positive tumor cells in patients with advanced colorectal cancer.
Mechanism of Action
GI-6301 works by presenting brachyury protein antigens to the immune system, specifically targeting the brachyury transcription factor that plays a critical role in epithelial-to-mesenchymal transition and cancer progression. The vaccine stimulates T-cell responses and antibody production against brachyury-expressing cancer cells, potentially leading to tumor cell destruction and enhanced immune surveillance.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 Estado EMA | Experimental |
 Acceso España | med_spain_not_available |
| Administration | Subcutaneous |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.